問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Infectious Disease

更新時間：2024-03-26

謝思民Hsieh, Szu-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

  • doceason1967@gmail.com

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝思民

List

29Cases

2008-03-01 - 2011-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-04-01 - 2022-06-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Terminated4Sites

2019-03-01 - 2023-10-07

Phase II

The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients

  • Condition/Disease

    HIV-1 Infection

  • Test Drug

    UB-421

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2015-07-01 - 2016-12-31

Phase III

A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1

  • Condition/Disease

    Multi-Drug Resistant HIV-1

  • Test Drug

    ibalizumab

Participate Sites
2Sites

Terminated2Sites

2010-09-01 - 2011-09-01

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-10-31 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2010-06-15 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-06-15 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-03-01 - 2011-05-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-12-25 - 2009-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB